欧洲心脏病学会0/1小时高敏肌钙蛋白T算法在已知冠心病患者90天随访中的表现
本研究为STOP-CP前瞻性队列的预设亚组分析,纳入8家美国中心急诊科≥21岁疑似急性冠脉综合征且初始心电图无ST段抬高的患者,按已知冠心病(既往心梗、血运重建或冠脉狭窄≥70%)分层,评估ESC 0/1-h hs-cTnT算法90天表现。已知冠心病患者占31.4%(449/1430),其90天心脏死亡或心梗发生率21.2%(95/449)高于无已知冠心病者的10.0%(98/981)(p<0.001)。被算法排除的患者中,已知冠心病者90天事件率3.4%(6/178)高于无已知冠心病者的1.2%(8/648)(p=0.09),阴性预测值分别为96.6%(95%CI 92.8-98.8)和98.8%(95%CI 97.6-99.5)(p=0.09)。作者认为该算法对已知冠心病患者可能不安全。
要点
- 已知冠心病患者中,ESC 0/1-h hs-cTnT算法排除后90天心脏死亡或心梗发生率为3.4%(6/178),高于无已知冠心病者的1.2%(8/648)(p=0.09)。
- 已知冠心病患者90天心脏死亡或心梗总发生率为21.2%(95/449),显著高于无已知冠心病者的10.0%(98/981)(p<0.001)。
- 已知冠心病患者被算法排除的比例为39.6%(178/449),低于无已知冠心病者的66.1%(648/981)(p<0.001)。
- 已知冠心病患者排除后阴性预测值为96.6%(95%CI 92.8-98.8),无已知冠心病者为98.8%(95%CI 97.6-99.5)(p=0.09)。
- 作者认为,ESC 0/1-h hs-cTnT算法可能不适用于已知冠心病患者。
适用人群与场景
- STOP-CP队列为前瞻性纳入的8家美国中心急诊科患者,年龄≥21岁,症状提示急性冠脉综合征,初始心电图无ST段抬高,纳入时间为2017年1月25日至2018年9月6日。
- 本分析按有无已知冠心病分层,已知冠心病定义为既往心肌梗死、冠状动脉血运重建或冠状动脉狭窄≥70%,由接诊医师判定。
诊断标准与关键阈值
- 采用ESC 0/1-h高敏肌钙蛋白T(hs-cTnT,罗氏,巴塞尔,瑞士)算法,将患者分为排除组、观察组和纳入组。
研究设计与关键结果
- 研究类型为STOP-CP前瞻性队列的预设亚组分析,纳入1430例患者,其中31.4%(449/1430)有已知冠心病。
- 主要终点为90天心脏死亡或心肌梗死,已知冠心病组发生率为21.2%(95/449),无已知冠心病组为10.0%(98/981)(p<0.001)。
- 使用ESC 0/1-h算法,已知冠心病组排除率为39.6%(178/449),无已知冠心病组为66.1%(648/981)(p<0.001)。
- 排除组中,已知冠心病患者90天心脏死亡或心梗发生率为3.4%(6/178),无已知冠心病患者为1.2%(8/648)(p=0.09)。
- 排除组90天心脏死亡或心梗的阴性预测值:已知冠心病患者96.6%(95%CI 92.8-98.8),无已知冠心病患者98.8%(95%CI 97.6-99.5)(p=0.09)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究的预设亚组分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,ESC 0/1-h hs-cTnT算法可能不适用于已知冠心病患者,因该组被排除后90天心脏事件发生率仍较高。
- 对已知冠心病患者使用该算法排除时,需注意其90天心脏死亡或心梗发生率为3.4%(6/178),阴性预测值为96.6%(95%CI 92.8-98.8)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The European Society of Cardiology (ESC) 0/1-h high sensitivity troponin T (hs-cTnT) algorithm does not differentiate risk based on known coronary artery disease (CAD: prior myocardial infarction [MI], coronary revascularization, or ≥ 70% coronary stenosis). We recently evaluated its performance among patients with known CAD at 30-days, but little is known about its longer-term risk prediction. The objective of this study is to determine and compare the performance of the algorithm at 90-days among patients with and without known CAD.
METHODS: We performed a pre-planned subgroup analysis of the STOP-CP cohort, which prospectively enrolled ED patients ≥21 years old with symptoms suggestive of ACS without ST-elevation on initial ECG across 8 US sites (1/25/2017-9/6/2018). Participants with 0- and 1-h hs-cTnT measures (Roche, Basel, Switzerland) were stratified into rule-out, observe, and rule-in groups using the ESC 0/1-h algorithm. Algorithm performance was tested among patients with or without known CAD, as determined by the treating provider. The primary outcome was cardiac death or MI at 90-days. Fisher's exact tests were used to compare 90-day event and rule-out rates between patients with and without known CAD. Negative predictive values (NPVs) for 90-day cardiac death or MI with exact 95% confidence intervals were calculated and compared using Fisher's exact test.
RESULTS: The STOP-CP study accrued 1430 patients, of which 31.4% (449/1430) had known CAD. Cardiac death or MI at 90 days was more common in patients with known CAD than in those without [21.2% (95/449) vs. 10.0% (98/981); p < 0.001]. Using the ESC 0/1-h algorithm, 39.6% (178/449) of patients with known CAD and 66.1% (648/981) of patients without known CAD were ruled-out (p < 0.001). Among rule-out patients, 90-day cardiac death or MI occurred in 3.4% (6/178) of patients with known CAD and 1.2% (8/648) without known CAD (p = 0.09). NPV for 90-day cardiac death or MI was 96.6% (95%CI 92.8-98.8) among patients with known CAD and 98.8% (95%CI 97.6-99.5) in patients without known CAD (p = 0.09).
CONCLUSION: Patients with known CAD who were ruled-out using the ESC 0/1-h hs-cTnT algorithm had a high rate of missed 90-day cardiac events, suggesting that the ESC 0/1-h hs-cTnT algorithm may not be safe for use among patients with known CAD.
TRIAL REGISTRATION: High-Sensitivity Cardiac Troponin T to Optimize Chest Pain Risk Stratification (STOP-CP; ClinicalTrials.gov: NCT02984436; https://clinicaltrials.gov/ct2/show/NCT02984436).
参考来源
- Ashburn NP, Snavely AC, Allen BR, et al. Performance of the European Society of Cardiology 0/1-hour algorithm with high-sensitivity cardiac troponin T at 90 days among patients with known coronary artery disease. Am J Emerg Med. 2024. PMID: 38417221. doi:10.1016/j.ajem.2024.02.029
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。